Tiny Feet
Tiny Feet
Tiny Feet

Pioneering novel biotherapeutics

for men and women struggling
with infertility.

Our new website is coming soon.

Tiny Feet

Igyxos Biotherapeutics' first clinical candidate, IGX12, is a first-in-class humanized monoclonal antibody that enhances the activity of follicle-stimulating hormone (FSH), a key hormone involved in infertility treatments for both men and women. The company’s transformational approach involves developing IGX12 as a more effective/efficient infertility treatment for patients. The company has successfully raised Series A funds and has been identified by La French Tech as one of France’s top 120 start-up companies for 2021.

Be among the first to get notified when the Igyxos corporate website is launched.

Thanks for your interest in Igyxos!!